Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liwanli Innovation CoTPE:3054 -1.38%62 Cash Ratio is 3.69 as of Jun. 2026, which is 62% below its 10-year median of 9.78. GuruFocus rates TPE:3054 with a GF Score™ of 62/100 and a GF Value™ of NT$120.11 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 967 Drug Manufacturers companies, Liwanli Innovation Co ranks better than 88.11% on this metric.
Liwanli Innovation Co has a Cash Ratio of 3.69. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Liwanli Innovation Co's Cash Ratio or its related term are showing as below:
TPE:3054'
s Cash Ratio Range Over the Past 10 Years
Min: 1.37 Med: 9.78 Max: 18.53
Current: 3.69
During the past 13 years, Liwanli Innovation Co's highest Cash Ratio was 18.53. The lowest was 1.37. And the median was 9.78.
TPE:3054's Cash Ratio is ranked better than 88.11% of 967
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs TPE:3054: 3.69
Liwanli Innovation Co (TPE:3054) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a Cash Ratio of 3.69 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Liwanli Innovation Co and its competitors. This is 62% below median its historical median of 9.78. Over the past decade, Liwanli Innovation Co's Cash Ratio has ranged from 1.37 to 18.53. According to the industry distribution chart, Liwanli Innovation Co ranks #115 out of 967 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Liwanli Innovation Co's Cash Ratio too high?
Liwanli Innovation Co's current Cash Ratio of 3.69 is 62% below median its 10-year median of 9.78. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 18.53. The Drug Manufacturers industry median Cash Ratio is 0.57. Liwanli Innovation Co's value of 3.69 is 547.4% above this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #115 out of 967 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Liwanli Innovation Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #115 out of 967 companies for Cash Ratio. This places Liwanli Innovation Co in the top 12% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.57. Liwanli Innovation Co's value of 3.69 is 547.4% above this benchmark. Historically, Liwanli Innovation Co's own Cash Ratio has ranged from 1.37 to 18.53 over the past decade. While the company's 10-year median is 9.78 vs. the industry median of 0.57, Liwanli Innovation Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current Cash Ratio of 3.69 is 547.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current Cash Ratio is 3.69, which is 62% below median its own 10-year median of 9.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Possible Value Trap. The stock's GF Value™ is NT$120.11, compared to a current price of NT$57.00 — trading 52.5% below its estimated fair value. The current Cash Ratio is 3.69, which is 62% below median its 10-year median of 9.78 and 547.4% above the Drug Manufacturers industry median of 0.57. Liwanli Innovation Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current Cash Ratio is 3.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be undervalued.
The current stock price of NT$57.00 is trading 52.5% below its estimated GF Value™ of NT$120.11.
GuruFocus considers Liwanli Innovation Co to be Possible Value Trap.
Key valuation signals for TPE:3054:
Cash Ratio: 3.69 (62% below median its 10-year median of 9.78)
GF Value™: NT$120.11 vs. price of NT$57.00 (52.5% below fair value)
Industry Position: 547.4% above the Drug Manufacturers median (#115 of 967)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
62GF Score
Get the complete analysis for TPE:3054
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
